Correlation between CA-125 serum level and response by RECIST in a phase III recurrent ovarian cancer study.
Herzog TJ, Vermorken JB, Pujade-Lauraine E, Provencher DM, Jagiello-Gruszfeld A, Kong B, Boman K, Park YC, Parekh T, Lebedinsky C, Gómez J, Monk BJ.
Herzog TJ, et al. Among authors: monk bj.
Gynecol Oncol. 2011 Aug;122(2):350-5. doi: 10.1016/j.ygyno.2011.04.005. Epub 2011 May 5.
Gynecol Oncol. 2011.
PMID: 21546066
Clinical Trial.